VISITECT® COVID-19 antigen test performs with the same high accuracy on the Omicron variant
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, has been notified by its technology partner Mologic Ltd (“Mologic”) that data from analysis on clinical samples, as well as in-silico analysis, show that the Mologic Covios® Ag lateral flow test, performs with the same high accuracy on the Omicron variant as it does with existing known variants.
This is the same test that is manufactured and sold for professional use by Omega as the VISITECT® COVID-19 antigen test.
Colin King, CEO, Omega Diagnostics, said: “We are very pleased be in a position to confirm that the VISITECT® COVID-19 antigen test is able to equally detect the Omicron variant, as well as other existing variants. We remain encouraged by emerging commercial opportunities for our VISITECT® COVID-19 Antigen test that we expect to be unlocked following relevant approval under CTDA regulations and CE-marking for home-use.”
Contacts:
Omega Diagnostics Group PLC
Colin King, Chief Executive Officer
via Walbrook PR
Chris Lea, Chief Financial Officer
